Cannabis, schizophrenia genetic risk, and psychotic experiences: a cross-sectional study of 109,308 participants from the UK Biobank

by Michael Wainberg, Grace R. Jacobs, Marta di Forti, Shreejoy J. Tripathy
Published 2021-04-01

Clinical laboratory tests and five-year incidence of major depressive disorder: a prospective cohort study of 433,890 participants from the UK Biobank

by Michael Wainberg, Stefan Kloiber, Breno Diniz, Roger S. McIntyre, Daniel Felsky, Shreejoy J. Tripathy
Published 2021-07-01

Homogeneity in the association of body mass index with type 2 diabetes across the UK Biobank: A Mendelian randomization study.

by Michael Wainberg, Anubha Mahajan, Anshul Kundaje, Mark I McCarthy, Erik Ingelsson, Nasa Sinnott-Armstrong, Manuel A Rivas
Published 2019-12-01

Rare protein-altering variants in ANGPTL7 lower intraocular pressure and protect against glaucoma.

by Yosuke Tanigawa, Michael Wainberg, Juha Karjalainen, Tuomo Kiiskinen, Guhan Venkataraman, Susanna Lemmelä, Joni A Turunen, Robert R Graham, Aki S Havulinna, Markus Perola, Aarno Palotie, FinnGen, Mark J Daly, Manuel A Rivas
Published 2020-05-01

Genome-scale measurement of off-target activity using Cas9 toxicity in high-throughput screens

by David W. Morgens, Michael Wainberg, Evan A. Boyle, Oana Ursu, Carlos L. Araya, C. Kimberly Tsui, Michael S. Haney, Gaelen T. Hess, Kyuho Han, Edwin E. Jeng, Amy Li, Michael P. Snyder, William J. Greenleaf, Anshul Kundaje, Michael C. Bassik
Published 2017-05-01

Mitigation of off-target toxicity in CRISPR-Cas9 screens for essential non-coding elements

by Josh Tycko, Michael Wainberg, Georgi K. Marinov, Oana Ursu, Gaelen T. Hess, Braeden K. Ego, Aradhana, Amy Li, Alisa Truong, Alexandro E. Trevino, Kaitlyn Spees, David Yao, Irene M. Kaplow, Peyton G. Greenside, David W. Morgens, Douglas H. Phanstiel, Michael P. Snyder, Lacramioara Bintu, William J. Greenleaf, Anshul Kundaje, Michael C. Bassik
Published 2019-09-01